Bradykinin receptor antagonists - A review of the patent literature 2005-2008

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 7, 2009, Pages 919-941

  Fincham, Christopher I ^a   Bressan, Alessandro ^a   Paris, Marielle ^a   Rossi, Cristina ^a   Fattori, Daniela ^a,b  

^a Menarini Ricerche SpA   (Italy)

^b NONE   (Italy)

Author keywords

BK antagonists; BK receptor; Bradykinin; Patent

Indexed keywords

AMG 379; BRADYKININ; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; ELN 441958; FIRAZYR; ICATIBANT; LF22 0545; MARTINELLINE; MEN 16132; MK 0686; TAPENTADOL; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; PAIN; PATENT; POSTHERPETIC NEURALGIA; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2;

EID: 67650422046     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902994389     Document Type: Review

References (98)

1. Burke JE, Cheronis JC, Whalley ET. Bradykinin receptor antagonists. Expert Opin Ther Patents 1995;5:331-340
2. Dziadulewicz EK. Non-peptide ligands for bradykinin receptors 1995-2004. Expert Opin Ther Patents 2005;15:829-859
3. Chen JJ, Johnson EJ. Targeting the bradykinin B1 Receptor to reduce pain. Expert Opin Ther Targets 2007;11:21-25 (Pubitemid 46099751)
4. Couture R, Harrisson M, Vianna RM, et al. Kinin receptors in pain and inflamamtion. Eur J Pharmacol 2001;429:829-859
5. Marceau F. Kinin B1 receptors: a review. Immunopharmacology 1995;30:1-26
6. Barnes PJ, Chung FK, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998;550:515-596
7. Foord SM, Bonner TI, Neubig RR, et al. International union of pharmacology. XLVI. G protein coupled receptor list. Pharmacol Rev 2005;57:279-288
8. Menke JG, Borkowski JA, Bierilo KK, et al. Expression cloning of a human B1 bradiykinin receptor. J Biol Chem 1994;269:21583-21586 (Pubitemid 24274792)
9. Mombouli JV, Vanhoutte PM. Endothelial dysfunction from physiology to therapy. J Mol Cell Cardiol 1999;31:61-74
10. Abraham WM, Scuri M, Farmer SG. Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. Eur J Pharm 2006;533:215-221 (Pubitemid 43340014)
11. Meini S, Maggi CA. Knee osteosrthritis: a role for bradykinin ? Inflamm Res 2008;57:351-361
12. Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nat Rev Drug Discov 2008;7:801-802
13. Chen JJ, Biswas K. Small molecule bradykinin B1 receptor antagonists as potential therapeutic agents for pain. Prog Med Chem 2008;46:173-204
14. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004;3:845-852 (Pubitemid 39405945)
15. Vavrek RJ, Steward JM. Competitive antagonists of bradykinin. Peptides 1985;6:161-164
16. Regoli D, Barabé J. Pharmacology of bradykinin and related kinin. Pharmacol Rev 1980;32:1-46
17. Individual. WO08607263; 1986
18. American Home Products Corp. US5212182; 1993
19. Merck & Co., Inc. WO9409001; 1994
20. Fujisawa Pharm. Co. Ltd. EP00596406; 1994
21. Fujisawa Pharm. Co. Ltd. EP00622361; 1994
22. Sanofi. Novel N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity. WO9725315; 1997
23. Amgen, Inc. Array Biopharma, Inc. Cyclic amine derivatives and methods of use. US20050234044; 2005
24. Amgen, Inc. Piperazine derivatives and methods of use. WO2005061467; 2005
25. D'Amico DC, Toshi A, Human J, et al. Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflamamtory activity. J Med Chem 2007;50:607-610 (Pubitemid 46332975)
26. Biswas K, Li A, Chen JJ, et al. Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides. J Med Chem 2007;50:2200-2212 (Pubitemid 46683073)
27. Biswas K, Toshihiro A, Qian W, et al. Aryl sulfones as novel bradykinin B1 receptor antagonists for treatment of chronic pain. Bioorg Med Chem Lett 2008;18:4764-4769
28. Amgen, Inc. Bradykinin 1 receptor antagonists.WO2007067629; 2007
29. Chen JJ, Wenyuan Q, Biswas K, et al. Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent bradykinin B1 receptor antagonists. Bioorg Med Chem Lett 2008;18:4477-4481
30. Amgen, Inc. Antagonists of the bradykinin B1 receptor. WO2005042027; 2005
31. Amgen, Inc. Glycosylated peptide antagonists of the bradykinin B1 receptor. WO2008011168; 2008
32. Amgen, Inc. Sustained release formulations. WO2005105057; 2005
33. Amgen, Inc. Peptide sustained release compositions and uses thereof. WO2006116565; 2006
34. Available from: http://wwwext.amgen.com/science/pipe.jsp [Last accessed 3 March 2009]
35. Boehringer Ingelheim Int. GMBH. Novel bradykinin antagonists, method for producing the same and use thereof as drugs. WO2006048209; 2006
36. Boehringer Ingelheim Int. GMBH. Aryl sylfonamides with an analgesic action. WO2008022945; 2008
37. Boehringer Ingelheim Int. GMBH. Novel B1 antagonists. WO2009013299; 2009
38. Dressen D, Garofalo AW, Hawkinson J, et al. Preparation and optimization of a series of 3-Carboxamido-5-phenacylaminopyrazole bradykinin B1 receptor antagonists. J Med Chem 2007;50:5161-5167 (Pubitemid 47585713)
39. Elan Pharmaceutical, Inc. Novel compounds useful for bradykinin B1 receptor antagonism. WO2006071775; 2006
40. Elan Pharmaceutical, Inc. Novel compounds useful for bradykinin B1 receptor antagonism. WO2006113140; 2006
41. Hawkinson JE, Szoke BG, Garofalo AW, et al. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 receptor antagonist ELN441958. J Pharm Exp Ther 2007;332:619-630
42. Evotec Neurosciences GMBH. New bradykinin B1 antagonists. WO2008125570; 2008
43. Richter Gedeon Vegyészeti Gyár RT. New phenanthridine derivatives as bradykinin antagonists. WO2007072092; 2007
44. Richter Gedeon Nyrt. New phenylsulfamoyl benzamide derivatives as bradykinin antagonists. WO2008050167; 2008
45. Richter Gedeon Nyrt. New sulfonamide derivatives as bradykinin antagonists. WO2008050168; 2008
46. Richter Gedeon Nyrt. New benzamide derivatives as bradykinin antagonists. WO2008068540; 2008
47. Grünenthal GMBH. Substituted sulfonamide derivatives. WO2008040492; 2008
48. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, mepridine, and brain stem stimulation in rats and cats. Pain 1977;4:161-174 (Pubitemid 8234766)
49. Grünenthal GMBH. Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators. WO2008046573; 2008
50. Grünenthal GMBH. Substituted amide derivatives. WO2008131946; 2008
51. Grünenthal GMBH. Substituted sulfonamide derivatives. WO2008131947; 2008
52. Jerini AG. Use of kinin antagonists. WO2007003411; 2007
53. Jerini AG. 8-Oxy-quinoline derivatives as bradykinin B2 receptor modulators. WO2008116620; 2008
54. Istituto Lusofarmaco D'Italia S.p.A. Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom. WO2006040004; 2006
55. Menarini Ricerche S.p.A. Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom. WO2003103671; 2003
56. Fattori D, Rossi C, Fincham CI, et al. Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 1. Synthesis and SAR of a,a-dimethylglycine sulfonamides. J Med Chem 2006;49:3602-3613
57. Fattori D, Rossi C, Fincham CI, et al. Design and synthesis of novel sulfonamide-containin bradykinin hB2 receptor antagonists. 2. Synthesis and structure-activity relationships of a,a-cycloalkylglycine sulfonamides. J Med Chem 2007;50:550-565
58. Cucchi P, Meini S, Bressan A, et al. MEN 16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. Invitro pharmacology and molecular characterization. Eur J Pharmacol 2005;528:7-16 (Pubitemid 41773646)
59. Feng DM, Wai JM, Kuduk SD, et al. 2,3-Diaminopyridine as a platform for designing structurally unique nonpeptide bradykinin B1 receptor antagonists. Bioorg Med Chem Lett 2005;15:2385-2388
60. Kuduk SD, Chang RK, Ng C, et al. Bradykinin B1 antagonists: SAR studies in the 2,3-diaminopyridne series. Bioorg Med Chem Lett 2005;15:3925-3929 (Pubitemid 41095496)
61. Merck & Co., Inc. 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation. US20050261327; 2005
62. Su DS, Lim JL, Markowitz MK, et al. Potent bradykinin B1 receptor antagonists: 4-Substituted phenyl cyclohexanes. Bioorg Med Chem Lett 2007;17:3006-3009 (Pubitemid 46702641)
63. Merck & Co., Inc. Substituted biaryl-carboxylate derivatives. US20060122236; 2006
64. Kuduk SD, Di Marco CN, Chang RK, et al. 5-Piperazyl pyridine carboxamide bradykinin B1 antagonists. Bioorg Med Chem Lett 2006;16:2791-2795
65. Merck & Co., Inc. 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation. US20060173023; 2006
66. Merck & Co., Inc. Sulfonyl susbtituted N-(biarylmethyl) aminocyclopropanecarboxamides. WO2005016886; 2005
67. Wood MR, Schirrippa MK, Kim JJ, et al. Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B receptor antagonists. J Med Chem 2006;49:1231-1234 (Pubitemid 43271878)
68. Kuduk SD, Di Marco CN, Chang RK, et al. Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists. J Med Chem 2007;50:272-282 (Pubitemid 46147708)
69. Feng DM, Di Pardo RM, Wai JM, et al. A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity. Bioorg Med Chem Lett 2008;18:682-687
70. Merck & Co., Inc. Aminocyclopropane carboxamide derivatives as bradykinin antagonists. WO2005085198; 2005
71. Merck & Co., Inc. 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation. US20060106011; 2006
72. Merck & Co., Inc. Substituted biaryl-carboxylate derivatives. US20060111392; 2006
73. Merck & Co., Inc. 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation. US20060128765; 2006
74. Merck & Co., Inc. Alpha-hydroxy amides as bradykinin antagonists or inverse agonists. WO2005063690; 2005
75. Wood MR, Schirripa KM, Kim JJ, et al. a-Hydroxy amides as novel class of bradykinin B1 selective antagonists. Bioorg Med Chem Lett 2008;18:716-720
76. Merck & Co., Inc. WO2006132837; 2006
77. Kuduk SD, Chang RK, DiPardo RM, et al. Bradykinin B1 receptor antagonists: an a-hydroxy amide with an improved metabolism profile. Bioorg Med Chem Lett 2008;18:5107-5110
78. Merck & Co., Inc. Arylsulfonamide derivatives. WO2005004810; 2005
79. Su DS, Lim JL, Tinney E, et al. 2-Aminobenzophenones as a novel class of bradykinin B1 receptor antagonists. J Med Chem 2008;51:3946-3952 (Pubitemid 351956522)
80. Available from: www.clinicaltrials.gov NCT00282763, NCT00296569 and NCT00533403, respectively
81. Tang C, Carr BA, Poignant F, et al. CYP2C75-involved autoinduction of metabolism in rhesus monkeys of methyl 3-chloro-3-fluoro-4-{(1R)-1-[({1- [(trifluoroacetyl)amino]cyclopropyl}carbonyl)amino]ethyl}-1,1-biphenyl-2- carboxylate (MK-0686), a bradykinin B1 receptor antagonist. J Pharm Exp Ther 2008;325:935-948 (Pubitemid 351724336)
82. Neurogen Corp. Aryl sulonyl heterocycles. WO200701007; 2007
83. Porrcea F, Vanderah TW, Guo W, et al. Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl) phenyl] methyl]-2-[2-[[(4-methoxy-2, 6-dimethylphenyl) sulphonyl] methylamino] ethoxy]-N-methylacetamide, Fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist. J Pharmacol Exp Ther 2006;318:195-205 (Pubitemid 43920756)
84. Neurogen Corporation. Spirocyclic sulfonamides and related compounds. WO2007140383; 2007
85. Neurogen Corporation. Aryl Sulfones. WO2008002849; 2008
86. Neurogen Corporation. N-oxide aryl sulfones and sulfoxides. WO2008024692; 2008
87. Neurogen Corporation. Benzimidazole carboxamide derivatives. WO2008033739; 2008
88. Guo Q, Jayaraman C, Ihle D, et al. 1-Benzylbenzimidazoles: the discovery of a novel series of bradykinin B1 receptor antagonists. Bioorg Med Chem Lett 2008;18:5027-5031
89. Université de Sherbrooke. New peptidic and peptidoid bradykinin B1 receptor antagonists and eses thereof. WO2006017938; 2006
90. Université de Sherbrooke. Selective bradykinin (BK) B1 peptidic receptor antagonists and uses thereof. US7211566; 2007
91. Park Choo. Pain-relieving composition. WO2007108566; 2007
92. Park Choo. New non-peptide compounds, process for the preparation thereof and pharmaceutical composition comprising the same. WO2007142431; 2007
93. The regents of the University of Colorado. Composition and methods for treating bone cancer. WO2008124756; 2008
94. Beltrami L, Zingale LC, Carugo S, et al. Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin Drug Saf 2006;5:643-649 The authors thank one of the referees for pointing out this potential use for B2R antagonists (Pubitemid 44322882)
95. Available from: www.xytis.com/Pipeline/xy2405.html; [Last accessed 13 April 2009]
96. Dias JP, Ismael MA, Pilon M, et al. The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol 2007;152:280-287 (Pubitemid 47517611)
97. Hara DB, Leite DFP, Fernandes ES, et al. The relevance of kinin B1 receptor upregulation in a mouse model of colitis. Br J Pharmacol 2008;154:1276-1286 (Pubitemid 351992071)
98. Pietrovski EF, Otuki MF, Regoli D, et al. The non-peptide kinin receptor antagonists FR173657 and SSR 240612: preclinical evidence for the treatment of skin inflammation. Reg Peptides 2009;152:67-72